The European Medicines Agency (EMEA) has recommended the suspension of the marketing authorization of Johnson & Johnson's painkiller skin patch Ionsys (fentanyl HCl) because of a defect with the drug delivery system that could lead to overdosing.
The product was cleared in Europe in January 2006 and is indicated for the management in hospital of acute moderate-to-severe post-operative pain. The EMEA's Committee for Medicinal Products for Human Use (CHMP) was informed by J&J unit Janssen-Cilag that it had detected corrosion of a component of the drug-delivery system in a batch of Ionsys that could trigger self-activation. In September, J&J voluntarily withdrew the patch from the European market as a precaution. Patients have been switched to alternatives.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze